HAYWARD, Calif., Feb. 10, 2015 /PRNewswire/ -- Anthera
Pharmaceuticals (NASDAQ: ANTH) today announced that the company has
received formal notification from the Nasdaq Stock Market
("Nasdaq"), indicating that the Company has regained compliance
with Listing Rule 5450(b)(1)(A), which requires a minimum of
$10,000,000 in stockholders' equity
or maintaining a market value of $50,000,000 or greater for ten consecutive
business days. Nasdaq has determined that Anthera
has maintained market value of at least $50,000,000 for the last ten consecutive business
days and as such, the Company has met alternative listing
requirements for continued listing.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company
focused on developing and commercializing products to treat serious
and life-threatening diseases, including systemic lupus
erythematosus, IgA nephropathy, and exocrine pancreatic
insufficiency due to cystic fibrosis.
Safe Harbor Statement
Any statements contained in this press release that refer to
future events or other non-historical matters, including statements
that are preceded by, followed by, or that include such words as
"estimate," "intend," "anticipate," "believe," "plan," "goal,"
"expect," "project," or similar statements, are forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on Anthera's expectations as
of the date of this press release and are subject to certain risks
and uncertainties that could cause actual results to differ
materially as set forth in Anthera's public filings with
the SEC, including Anthera's Annual Report on Form 10-K for
the year ended December 31, 2013 and Quarterly Report on
Form 10-Q for the quarter ended September 30, 2014.
Anthera disclaims any intent or obligation to update any
forward-looking statements, whether because of new information,
future events or otherwise, except as required by applicable
law.
CONTACT: Dennis Lutz of Anthera Pharmaceuticals,
Inc., dlutz@anthera.com or 510.856.5598.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/anthera-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements-300034055.html
SOURCE Anthera Pharmaceuticals, Inc.